Sequence variants of estrogen receptor B and risk of prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium

Cancer Epidemiology Biomarkers and Prevention

Volumn 16, Issue 10, 2007, Pages 1973-1981

  Chen, Yen Ching ^a,c,v   Kraft, Peter ^b   Bretsky, Philip ^d   Ketkar, Shamika ^e   Hunter, David J ^a,b   Albanes, Demetrius ^f   Altshuler, David ^g   Andriole, Gerald ^t   Berg, Christine D ^f   Boeing, Heiner ^h   Burtt, Noel ^g   Bueno de Mesquita, Bas ⁱ   Cann, Howard ^j   Canzian, Federico ^k   Chanock, Stephen ^f   Dunning, Alison ^l   Feigelson, Heather S ^m   Freedman, Matthew ^j   Gaziano, J Michael ^a   Giovannucci, Edward ^b   Sánchez, Maria Jose ⁿ   Haiman, Christopher A ^d   Hallmans, Göran ^o   Hayes, Richard B ^f   Henderson, Brian E ^d   Hirschhorn, Joel ^g   Kaaks, Rudolf ^p   Key, Timothy J ^q   Kolonel, Laurence N ^r   Lemarchand, Loic ^r   Ma, Jing ^a   Overvad, Kim ^s   Palli, Domenico ^t   Pharaoh, Paul ^l   Pike, Malcolm ^d   Riboli, Eliot ^k   Rodriguez, Carmen ^m   Setiawan, V Wendy ^d   Stampfer, Meir ^b   Stram, Daniel O ^d   Thomas, Gilles ^j   Thun, Michael J ^k   Travis, Ruth C ^q   Virtamo, Jarmo ^r   Trichopoulou, Antonia ^u   Wacholder, Sholom ^f   Weinstein, Stephanie J ^f   more..

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e WASHINGTON UNIVERSITY   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

^g BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^h GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

ⁱ NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^j FONDATION JEAN DAUSSET CEPH   (France)

^k INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^l UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^m AMERICAN CANCER SOCIETY   (United States)

ⁿ Andalusian Health Service   (Spain)

^o UMEÅ UNIVERSITY   (Sweden)

^p GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^q IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^r UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^s AALBORG UNIVERSITY HOSPITAL   (Denmark)

^t CANCER RESEARCH AND PREVENTION INSTITUTE ISPO   (Italy)

^u UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^v CHANNING LABORATORY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR BETA;

APOPTOSIS; ARTICLE; BODY MASS; BREAST CANCER; CANCER RISK; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; DEMOGRAPHY; FAMILY HISTORY; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSTATE CANCER; RACE DIFFERENCE; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; COHORT STUDIES; ESTROGEN RECEPTOR BETA; EXONS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; MALE; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROSTATIC NEOPLASMS; RISK ASSESSMENT; SEQUENCE ANALYSIS, DNA; VARIATION (GENETICS);

EID: 35448930679     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-0431     Document Type: Article

References (40)

1. Pettersson K, Gustafsson JA. Role of estrogen receptor β in estrogen action. Annu Rev Physiol 2001;63:165-92.
2. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A 1996;93:5925-30.
3. Nilsson S, Makela S, Treuter E, et al. Mechanisms of estrogen action. Physiol Rev 2001;81:1535-65.
4. Kuiper GG, Carlsson B, Grandien K, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology 1997;138:863-70.
5. Harkonen PL, Makela SI. Role of estrogens in development of prostate cancer. J Steroid Biochem Mol Biol 2004;92:297-305.
6. Kuiper GG, Gustafsson JA. The novel estrogen receptor-β subtype: potential role in the cell- and promoter-specific actions of estrogens and anti-estrogens. FEBS Lett 1997;410:87-90.
7. Bardin A, Boulle N, Lazennec G, Vignon F, Pujol P. Loss of ERβ expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer 2004;11:537-51.
8. Ji Q, Liu PI, Elshimali Y, Stolz A. Frequent loss of estrogen and progesterone receptors in human prostatic tumors determined by quantitative real-time PCR. Mol Cell Endocrinol 2005;229:103-10.
9. Pasquali D, Rossi V, Esposito D, et al. Loss of estrogen receptor {β} expression in malignant human prostate cells in primary cultures and in prostate cancer tissues. J Clin Endocrinol Metab 2001;86:2051-5.
10. Latil A, Bieche I, Vidaud D, et al. Evaluation of androgen, estrogen (ER α and ER β), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res 2001;61:1919-26.
11. Cheng J, Lee EJ, Madison LD, Lazennec G. Expression of estrogen receptor β in prostate carcinoma cells inhibits invasion and proliferation and triggers apoptosis. FEBS Lett 2004;566:169-72.
12. Hunter DJ, Riboli E, Haiman CA, et al. A candidate gene approach to searching for low-penetrance breast and prostate cancer genes. Nat Rev Cancer 2005;5:977-85.
13. Calle EE, Rodriguez C, Jacobs EJ, et al. The American Cancer Society Cancer Prevention Study II Nutrition Cohort: rationale, study design, and baseline characteristics. Cancer 2002;94:2490-501.
14. The α-tocopherol, β-carotene lung cancer prevention study: design, methods, participant characteristics, and compliance. The ATBC Cancer Prevention Study Group. Ann Epidemiol 1994;4:1-10.
15. Riboli E, Hunt KJ, Slimani N, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr 2002;5:1113-24.
16. Giovannucci E, Pollak M, Liu Y, et al. Nutritional predictors of insulin-like growth factor I and their relationships to cancer in men. Cancer Epidemiol Biomarkers Prev 2003;12:84-9.
17. Kolonel LN, Altshuler D, Henderson BE. The multiethnic cohort study: exploring genes, lifestyle and cancer risk. Nat Rev Cancer 2004;4:519-27.
18. Chan JM, Stampfer MJ, Ma J, et al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 2002;94:1099-106.
19. Hayes RB, Reding D, Kopp W, et al. Etiologic and early marker studies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin Trials 2000;21:349-55S.
20. Kraft P, Pharoah P, Chanock SJ, et al. Genetic variation in the HSD17B1 gene and risk of prostate cancer. PLoS Genet 2005;1:e68.
21. Gabriel SB, Schaffner SF, Nguyen H, et al. The structure of haplotype blocks in the human genome. Science 2002;296:2225-9.
22. Stram DO, Haiman CA, Hirschhorn JN, et al. Choosing haplotype-tagging SNPS based on unphased genotype data using a preliminary sample of unrelated subjects with an example from the Multiethnic Cohort Study. Hum Hered 2003;55:27-36.
23. de Bakker PI, Burtt NP, Graham RR, et al. Transferability of tag SNPs in genetic association studies in multiple populations. Nat Genet 2006;38:1298-303.
24. De Bakker PI, Graham RR, Altshuler D, Henderson BE, Haiman CA. Transferability of tag SNPs to capture common genetic variation in DNA repair genes across multiple populations. Pac Symp Biocomput 2006;11:478-86.
25. Montpetit A, Nelis M, Laflamme P, et al. An evaluation of the performance of tag SNPs derived from HapMap in a Caucasian population. PLoS Genet 2006;2:e27.
26. Need AC, Goldstein DB. Genome-wide tagging for everyone. Nat Genet 2006;38:1227-8.
27. Conrad DF, Jakobsson M, Coop G, et al. A worldwide survey of haplotype variation and linkage disequilibrium in the human genome. Nat Genet 2006;38:1251-60.
28. Packer BR, Yeager M, Staats B, et al. SNP500Cancer: a public resource for sequence validation and assay development for genetic variation in candidate genes. Nucleic Acids Res 2004;32:D528-32.
29. SNPHAP: A program for estimating frequencies of large haplotypes of SNPs Version 1.0: Cambridge: Department of Medical Genetics, Cambridge Institute for Medical Research.
30. Qin ZS, Niu T, Liu JS. Partition-ligation-expectation-maximization algorithm for haplotype inference with single-nucleotide polymorphisms. Am J Hum Genet 2002;71:1242-7.
31. Kraft P, Cox DG, Paynter RA, Hunter D, De Vivo I. Accounting for haplotype uncertainty in matched association studies: a comparison of simple and flexible techniques. Genet Epidemiol 2005;28:261-72.
32. Kalish LA, McDougal WS, McKinlay JB. Family history and the risk of prostate cancer. Urology 2000;56:803-6.
33. Cerhan JR, Parker AS, Putnam SD, et al. Family history and prostate cancer risk in a population-based cohort of Iowa men. Cancer Epidemiol Biomarkers Prev 1999;8:53-60.
34. Hsing AW. Hormones and prostate cancer: what's next? Epidemiol Rev 2001;23:42-58.
35. Buschemeyer Iii WC, Freedland SJ. Obesity and Prostate Cancer: Epidemiology and Clinical Implications. Eur Urol 2007;52:331-43.
36. Thellenberg-Karlsson C, Lindstrom S, Malmer B, et al. Estrogen receptor β polymorphism is associated with prostate cancer risk. Clin Cancer Res 2006;12:1936-41.
37. Yeager M. SP16 Whole-genome association and replication studies in prostate cancer. J Biomol Tech 2007;18:84.
38. Maggiolini M, Recchia AG, Carpino A, et al. Oestrogen receptor β is required for androgen-stimulated proliferation of LNCaP prostate cancer cells. J Mol Endocrinol 2004;32:777-91.
39. Fixemer T, Remberger K, Bonkhoff H. Differential expression of the estrogen receptor β (ERβ) in human prostate tissue, premalignant changes, and in primary, metastatic, and recurrent prostatic adenocarcinoma. Prostate 2003;54:79-87.
40. Prins GS, Marmer M, Woodham C, et al. Estrogen receptor-β messenger ribonucleic acid ontogeny in the prostate of normal and neonatally estrogenized rats. Endocrinology 1998;139:874-83.